Group 1 - The core viewpoint of the article highlights the successful publication of clinical trial results for the combination therapy of KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 in a leading medical journal, marking a significant milestone in cancer treatment [1] - The open-label Phase I/IIa clinical study conducted in China included 171 patients with KRAS G12C mutated non-small cell lung cancer (NSCLC), demonstrating a 71% objective response rate (ORR) and a median progression-free survival (mPFS) of 12.2 months in treatment-naive patients [1] - This combination therapy shows a competitive edge over the current standard treatment of immunotherapy plus chemotherapy, indicating its potential as a leading first-line treatment option [1] Group 2 - Currently, the KRAS G12C and SHP2 inhibitors are undergoing Phase III clinical trials in China, which will directly compare this combination therapy with existing standard treatment pathways [2] - The aim is to position this dual oral therapy as the first SHP2 combination treatment likely to receive global approval [2]
加科思-B(01167)：加科思KRAS G12C与SHP2联合疗法数据见刊《柳叶刀呼吸医学》